DE ROSA, Francesco Giuseppe

DE ROSA, Francesco Giuseppe  

SCIENZE MEDICHE  

Mostra records
Risultati 1 - 20 di 334 (tempo di esecuzione: 0.032 secondi).
Titolo Data di pubblicazione Autore(i) File
2018 WSES/SIS-E consensus conference: recommendations for the management of skin and soft-tissue infections 2018 Sartelli, Massimo; Guirao, Xavier; Hardcastle, Timothy C; Kluger, Yoram; Boermeester, Marja A; Raşa, Kemal; Ansaloni, Luca; Coccolini, Federico; Montravers, Philippe; Abu-Zidan, Fikri M; Bartoletti, Michele; Bassetti, Matteo; Ben-Ishay, Offir; Biffl, Walter L; Chiara, Osvaldo; Chiarugi, Massimo; Coimbra, Raul; De Rosa, Francesco Giuseppe; De Simone, Belinda; Di Saverio, Salomone; Giannella, Maddalena; Gkiokas, George; Khokha, Vladimir; Labricciosa, Francesco M; Leppäniemi, Ari; Litvin, Andrey; Moore, Ernest E; Negoi, Ionut; Pagani, Leonardo; Peghin, Maddalena; Picetti, Edoardo; Pintar, Tadeja; Pupelis, Guntars; Rubio-Perez, Ines; Sakakushev, Boris; Segovia-Lohse, Helmut; Sganga, Gabriele; Shelat, Vishal; Sugrue, Michael; Tarasconi, Antonio; Tranà, Cristian; Ulrych, Jan; Viale, Pierluigi; Catena, Fausto
2019 novel coronavirus (2019-nCoV) outbreak: A new challenge 2020 Lupia T.; Scabini S.; Mornese Pinna S.; Di Perri G.; De Rosa F.G.; Corcione S.
A 30-years Review on Pharmacokinetics of Antibiotics: Is the Right Time for Pharmacogenetics? 2014 Baietto, L; Corcione, S; Pacini, G; Di Perri, G; D'Avolio, A; De Rosa, FG
A man with chronic leg edema, purpuric skin lesions, and abdominal lymphadenopathy 2005 CRAVEN DE; TRONIC BS; SCHOLZ FJ; BEAN SM; F. DE ROSA; MUNSON JL
A short course of pegylated interferon-alpha in acute HCV hepatitis 2007 CALLERI G; CARITI G; GAIOTTINO F; DE ROSA FG; BARGIACCHI O; AUDAGNOTTO S; QUAGLIA S; DE BLASI T; ROMANO P; TRAVERSO A; LEO G; CARBONE R; DEL MASTRO B; TINELLI M; CARAMELLO P; DI PERRI G
A(H1N1)pdm09 hemagglutinin D222G and D222N variants are frequently harbored by patients requiring extracorporeal membrane oxygenation and advanced respiratory assistance for severe A(H1N1)pdm09 infection 2013 Ruggiero T;De Rosa F;Cerutti F;Pagani N;Allice T;Stella ML;Milia MG;Calcagno A;Burdino E;Gregori G;Urbino R;Di Perri G;Ranieri MV;Ghisetti V
Acquisition of FKS2 mutation after echinocandin treatment of infective endocarditis by Candida glabrata 2019 Corcione, Silvia; D'Avolio, Antonio; Pasero, Daniela; Trentalange, Alice; Pagani, Nicole; Sanguinetti, Maurizio; De Rosa, Francesco Giuseppe
Acute hepatitis C: dosage and compliance 2006 DE ROSA F; CARITI G; DI PERRI G
Aetiological diagnosis in acute and recurrent pericarditis: when and how 2009 Imazio M; Brucato A; Derosa FG; Lestuzzi C; Bombana E; Scipione F; Leuzzi S; Cecchi E; Trinchero R; Adler Y
Allergic rhinitis, olfactory disorders and secretory IgA 1996 B. S. Paparo;O. Leri;P. Andreoli;A. A. Chirra;M. Casagrande;M. A. Addessi;P. Sagnelli;F. G. De Rosa;M. Sagnelli
Amikacin dosing in the ICU: we now know more, but still not enough… 2014 De Rosa FG;Roberts JA
Amoebiasis and inflammatory bowel disease (our experience) 1995 L. Ceccarini; L. Antonelli; A. Teggi; F.G. De Rosa; F. Traditi
Analytical validation and clinical application of rapid serological tests for sars-cov-2 suitable for large-scale screening 2021 De Nicolò Amedeo.; Avataneo V.; Cusato J.; Palermiti A.; Mula J.; De Vivo E.; Antonucci M.; Bonora S.; Calcagno A.; Di Perri G.; De Rosa F.G.; D'avolio A.
Anidulafungin for Candida glabrata Infective Endocarditis 2012 De Rosa FG; D'Avolio A; Corcione S; Baietto L; Raviolo S; Centofanti P; Pasero D; Rinaldi M; Di Perri G.
Anidulafungin pharmacokinetic evaluation in a cohort of patients 2011 F.G. De Rosa; L. Baietto; A. D’Avolio; D. Pasero; S. Raviolo; S. Pace; C. Marra; V.M. Ranieri; G. Di Perri
Anidulafungin treatment in a kidney transplant recipientwith hepatic damage 2011 De Rosa FG; Manzione NA; Ranghino A; Messina M; Ottobrelli A; Raviolo S; Di Perri G; Segoloni GP
Anidulafungin versus fluconazole: clinical focus on IDSA and ESCMID guidelines. 2014 De Rosa FG;Motta I;Corcione S;Cattel F;Di Perri G;D'Avolio A
Antecedent Administration of Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Antagonists and Survival After Hospitalization for COVID-19 Syndrome 2020 Palazzuoli A.; Mancone M.; De Ferrari G.M.; Forleo G.; Secco G.G.; Ruocco G.M.; D'Ascenzo F.; Monticone S.; Paggi A.; Vicenzi M.; Palazzo A.G.; Landolina M.; Taravelli E.; Tavazzi G.; Blasi F.; Infusino F.; Fedele F.; De Rosa F.G.; Emmett M.; Schussler J.M.; Tecson K.M.; McCullough P.A.
Anti-neutrophil cytoplasmic antibodies in echinococcus granulosus hydatid disease 2001 F. G. De Rosa;A. Amoroso;A. Teggi;S. B. Paparo;C. Franchi;G. M. Ferri;D. Caccavo;A. Afeltra
Antibiotic de-escalation experience in the setting of emergency department: A retrospective, observational study 2021 Corcione S.; Mornese Pinna S.; Lupia T.; Trentalange A.; Germano E.; Cavallo R.; Lupia E.; De Rosa F.G.